The postnatal manifestation of retinal pathology in IMPG2-RP suggests it will be amenable to gene editing or gene addition therapeutic interventions — strategies that are facilitated by having relevant patient cell lines and animal models. Here, IMPG2 is linked to retinitis pigmentosa 1.